RxDoctor Payments Data

Elizabeth Reyes

Adult Health · Las Cruces, NMNPI 1306603121

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Bayer at 28.7% of the total.

$1,327in general payments, 2019–2025

Across 55 payments — averaging $24.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$381
  • Amgen$170
  • AstraZeneca$148
  • Aurinia Pharma U.S., Inc.$131
  • Otsuka America Pharmaceutical, Inc.$127
  • Medtronic$113
  • plus $257 from 8 others

What the payments were for

  • Food & beverage$1,327100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,327 in reported general payments places this provider in the 70th percentile of 52 adult health providers in New Mexico.

See all adult health providers in New Mexico

Medicare billing

Part B allowed, 2024
$31,166
Medicare patients
120
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin16$17,563
LokelmaSodium Zirconium Cyclosilicate11$15,840
Sevelamer Carbonate14$1,718
Midodrine Hcl12$981
Tamsulosin Hcl19$353
Potassium Citrate ErPotassium Citrate12$348
Gabapentin14$239
Losartan Potassium25$236
Chlorthalidone11$206
Potassium Chloride11$119
Lisinopril14$99
Furosemide19$92
Amlodipine Besylate18$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$38$17,56316 claims
AstraZenecaLokelma$148$15,84011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 52 adult health providers in New Mexico.

Other adult health in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →